AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1803847 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buffering lozenge (Profylin) after sucrose rinse
Number of subjects: 33
Study 1803847 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge after sucrose rinse
Number of subjects: 33
Study 6671105 — intervention group
Group type: EXPERIMENTAL
Intervention: Veridical auditory biofeedback
Number of subjects: 4
Study 6671105 — intervention group
Group type: COMPARATOR
Intervention: Auditory pseudofeedback (random signal)
Number of subjects: 4
Study 6671105 — intervention group
Group type: COMPARATOR
Intervention: Auditory pseudofeedback (gradually increasing frequency)
Number of subjects: 4
Study 6671105 — intervention group
Group type: COMPARATOR
Intervention: Auditory pseudofeedback (gradually decreasing frequency)
Number of subjects: 4
Study 31119846 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK‐100STP 120 μg
Number of subjects: 892
Study 31119846 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK‐100STP 240 μg
Number of subjects: 892
Study 31119846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892
Study 28273240 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser pan-retinal photocoagulation with intravitreal bevacizumab injections
Number of subjects: 19
Study 28273240 — intervention group
Group type: COMPARATOR
Intervention: Laser pan-retinal photocoagulation alone
Number of subjects: 19
Study 26649465 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT) with therapist support for 10 weeks
Number of subjects: 93
Study 26649465 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 93
Study 24385269 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care program (SMART group)
Number of subjects: 2717
Study 24385269 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 2717
Study 22323279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (integrating physical activity and nutrition practices into workplace routine during non-discretionary paid work time)
Number of subjects: 15
Study 22323279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 15
Study 21059433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 228
Study 21059433 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 228
Study 17973984 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture at LI4, ST36 and LV3
Number of subjects: 42
Study 17973984 — intervention group
Group type: COMPARATOR
Intervention: Tactile stimulation (sensory control)
Number of subjects: 42
Study 17973984 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 42
Study 17973984 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 acupuncture point
Number of subjects: 42
Study 15983390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 147
Study 15983390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 12476542 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine/pseudoephedrine (5 mg/240 mg)
Number of subjects: 1018
Study 12476542 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine (5 mg)
Number of subjects: 1018
Study 12476542 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine (240 mg)
Number of subjects: 1018
Study 9761434 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (Tegafur and Uracil) administered post-operatively to 98 patients
Number of subjects: 655
Study 9761434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UFT administered to 557 patients)
Number of subjects: 655
Study 9761434 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for p-stage I disease
Number of subjects: 655
Study 9761434 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for p-stage IIIa, pN2 disease
Number of subjects: 655
Study 9761434 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT efficacy in multivariate analysis
Number of subjects: 655
Study 7642053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (thrombolysis) for AMI
Number of subjects: 8025
Study 2767019 — intervention group
Group type: EXPERIMENTAL
Intervention: Meter-plus-contract
Number of subjects: 72
Study 2767019 — intervention group
Group type: COMPARATOR
Intervention: Meter-alone
Number of subjects: 72
Study 31074161 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane Lyft
Number of subjects: 100
Study 31074161 — intervention group
Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 100
Study 31074161 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane Lyft and Restylane
Number of subjects: 100
Study 28329389 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404
Study 28329389 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study 26337626 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive multicomponent intervention (home-based progressive strength, mobility and activities of daily living training)
Number of subjects: 22
Study 26337626 — intervention group
Group type: COMPARATOR
Intervention: Usual care rehabilitation (control group)
Number of subjects: 22
Study 24398761 — intervention group
Group type: EXPERIMENTAL
Intervention: n-hexyl-α-cyanoacrylate glue
Number of subjects: 208
Study 24398761 — intervention group
Group type: COMPARATOR
Intervention: Prolene sutures
Number of subjects: 208
Study 24398761 — intervention group
Group type: COMPARATOR
Intervention: Tackers
Number of subjects: 208
Study 22003058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling via a water-perfused suit
Number of subjects: 21
Study 19665606 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 clade 1 subunit vaccine
Number of subjects: 0
Study 19665606 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain H5N1 clade 1 subunit vaccine
Number of subjects: 0
Study 19665606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoparticle neutralization (PPN) assay
Number of subjects: 0
Study 19665606 — intervention group
Group type: COMPARATOR
Intervention: Hemagglutination inhibition (HI) assay
Number of subjects: 0
Study 19665606 — intervention group
Group type: COMPARATOR
Intervention: Viral micro‐neutralization (MN) assay
Number of subjects: 0
Study 17659909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2.0 g protein/kg/day)
Number of subjects: 22
Study 17659909 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.5 g protein/kg/day)
Number of subjects: 22
Study 16220761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin gel
Number of subjects: 91
Study 16220761 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study 16220761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sheet
Number of subjects: 91
Study 11895913 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D)
Number of subjects: 283
Study 11895913 — intervention group
Group type: COMPARATOR
Intervention: Sequential methotrexate and 5‐fluorouracil (MF)
Number of subjects: 283
Study 11895913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bcl‐2 expression
Number of subjects: 283
Study 11895913 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasL expression
Number of subjects: 283
Study 11895913 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl‐2
Number of subjects: 283
Study 11895913 — intervention group
Group type: EXPERIMENTAL
Intervention: fasL
Number of subjects: 283
Study 10362116 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 40 mg orally for 21 days
Number of subjects: 20
Study 10362116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7719395 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 4.5 kg or more from baseline to 6 months (mean weight loss of 11.8 kg or 13% of initial body weight)
Number of subjects: 159
Study 7719395 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 159
Study 1788754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE1
Number of subjects: 0
Study 1788754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Pentoxifylline
Number of subjects: 0
Study 1788754 — intervention group
Group type: COMPARATOR
Intervention: Training group (control)
Number of subjects: 0
Study 1788754 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline group (control)
Number of subjects: 0
Study 1788754 — intervention group
Group type: COMPARATOR
Intervention: PGE1 group (control)
Number of subjects: 0
Study 7259364 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (30 microgram/kg)
Number of subjects: 5
Study 7259364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (150 microgram/kg)
Number of subjects: 5
Study 7259364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic glucose solution)
Number of subjects: 5
Study 31653513 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PCSK9 monoclonal antibodies (mAbs) alirocumab or evolocumab
Number of subjects: 24
Study 30152298 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported 6-week online intervention based on cognitive behavioural therapy (iCBT)
Number of subjects: 36
Study 28706174 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing program (8 sessions, 60 minutes each, once a week)
Number of subjects: 62
Study 25698197 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 μg/kg) administered intravenously during re-warming
Number of subjects: 102
Study 25698197 — intervention group
Group type: COMPARATOR
Intervention: Control (saline administered intravenously during re-warming)
Number of subjects: 102
Study 23365113 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ-100)
Number of subjects: 220
Study 23365113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 21896879 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d
Number of subjects: 68
Study 21896879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19808125 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 1674
Study 19808125 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI 30)
Number of subjects: 1674
Study 19808125 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 1674
Study 19808125 — intervention group
Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 1674
Study 17343130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4360
Study 17343130 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4360
Study 17343130 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 4360
Study 17343130 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone vs Metformin
Number of subjects: 4360
Study 17343130 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone vs Glibenclamide
Number of subjects: 4360
Study 15670436 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based disease management and case management
Number of subjects: 8504
Study 15670436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8504
Study 11839457 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic red wine (3 glasses, consumed 1 hour apart)
Number of subjects: 0
Study 11839457 — intervention group
Group type: COMPARATOR
Intervention: Placebo red wine (3 glasses, consumed 1 hour apart)
Number of subjects: 0
Study 9737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 751
Study 9737646 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 1200 mg
Number of subjects: 751
Study 9737646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin and Gemfibrozil
Number of subjects: 751
Study 3071952 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus Anandron (300 mg daily)
Number of subjects: 98
Study 3071952 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 98
Study 29293181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent boluses (21 mL/3 h) of 0.2% ropivacaine
Number of subjects: 110
Study 29293181 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (7 mL/h) of 0.2% ropivacaine
Number of subjects: 110
Study 27669730 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG+G-CSF
Number of subjects: 25
Study 27669730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24070164 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 regimen (oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU bolus 400 mg/m², 5-FU infusion 600 mg/m²) administered every 2 weeks for two consecutive days.
Number of subjects: 37
Study 22552314 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar denervation by electrocautery
Number of subjects: 35
Study 22552314 — intervention group
Group type: COMPARATOR
Intervention: Debridement alone (control)
Number of subjects: 35
Study 19940093 — intervention group
Group type: COMPARATOR
Intervention: Flavored placebo with no electrolytes (P)
Number of subjects: 15
Study 19940093 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with electrolytes (P + E)
Number of subjects: 15
Study 19940093 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% carbohydrate solution with electrolytes
Number of subjects: 15
Study 19940093 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution with electrolytes
Number of subjects: 15
Study 19940093 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% carbohydrate solution with electrolytes
Number of subjects: 15
Study 19018917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-organizational integrated audits with feedback and presence of facilitators
Number of subjects: 0
Study 19018917 — intervention group
Group type: COMPARATOR
Intervention: Standard observation
Number of subjects: 0
Study 15813841 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy
Number of subjects: 226
Study 12020181 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-triggered treatment with oxazepam
Number of subjects: 117
Study 12020181 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule treatment with oxazepam
Number of subjects: 117
Study 10219832 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic flakes (24 g/day)
Number of subjects: 18
Study 10219832 — intervention group
Group type: EXPERIMENTAL
Intervention: Small granules (24 g/day)
Number of subjects: 18
Study 8751016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24
Study 8751016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2145400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg IV)
Number of subjects: 0
Study 2145400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7206593 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate (Urografin 76%) alone
Number of subjects: 15
Study 7206593 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate with added calcium (11.3 mmol/l)
Number of subjects: 15
Study 7206593 — intervention group
Group type: EXPERIMENTAL
Intervention: metrizamide (Amipaque)
Number of subjects: 15
Study 7206593 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 15
Study 31651690 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried status
Number of subjects: 5707
Study 31651690 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried status adjusted for traditional cardiovascular risk factors
Number of subjects: 5707
Study 31651690 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried status adjusted for coronary calcium score
Number of subjects: 5707
Study 30522969 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib plus obinutuzumab
Number of subjects: 229
Study 30522969 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil plus obinutuzumab
Number of subjects: 229
Study 27789095 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg twice a day (BID) for 4 weeks
Number of subjects: 112
Study 27789095 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Lovenox in conjunction with pneumatic compression devices (from a recent randomized controlled trial)
Number of subjects: 112
Study 26718672 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair with MitraClip device
Number of subjects: 258
Study 26718672 — intervention group
Group type: COMPARATOR
Intervention: Conventional MV surgery
Number of subjects: 258
Study 23244709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with CAPIRI or CAPOX
Number of subjects: 121
Study 21099675 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diabetes education (n = 61)
Number of subjects: 122
Study 21099675 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 61)
Number of subjects: 122
Study 18848401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 104
Study 18848401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 16709212 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-aid leaflet
Number of subjects: 328
Study 16709212 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 328
Study 15646218 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish
Number of subjects: 75
Study 15646218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity Shield varnish
Number of subjects: 75
Study 15646218 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflor varnish
Number of subjects: 75
Study 15646218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector varnish
Number of subjects: 75
Study 15646218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 75
Study 11417442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily
Number of subjects: 33
Study 11417442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily
Number of subjects: 33
Study 11417442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg once daily
Number of subjects: 33
Study 11417442 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times daily
Number of subjects: 33
Study 9924266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation (15 mg/d as mixed ester forms) for 4 months
Number of subjects: 18
Study 8313548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20
Study 8313548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham accent
Number of subjects: 72
Study 3372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Yorkshire accent
Number of subjects: 72
Study 3372884 — intervention group
Group type: EXPERIMENTAL
Intervention: South east educated accent
Number of subjects: 72
Study 3372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian accented English
Number of subjects: 72
Study 3372884 — intervention group
Group type: COMPARATOR
Intervention: Control group (south east educated accent)
Number of subjects: 72
Study 30224533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin 10 mg/kg (450 mg)
Number of subjects: 60
Study 30224533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin 20 mg/kg (900 mg)
Number of subjects: 60
Study 30224533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin 30 mg/kg (1,350 mg)
Number of subjects: 60
Study 30224533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin (all doses)
Number of subjects: 60
Study 30224533 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of rifampin
Number of subjects: 60
Study 26873163 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education information pamphlets
Number of subjects: 49
Study 26873163 — intervention group
Group type: COMPARATOR
Intervention: Verbal consent only
Number of subjects: 49
Study 26873163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 49
Study 26873163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-op HADS score
Number of subjects: 49
Study 25626851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with subtalar strapping
Number of subjects: 58
Study 25626851 — intervention group
Group type: COMPARATOR
Intervention: Neutral insole with subtalar strapping (Control)
Number of subjects: 58
Study 23271206 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-legged hopping (TLH)
Number of subjects: 17
Study 23271206 — intervention group
Group type: COMPARATOR
Intervention: One-legged hopping (OLH)
Number of subjects: 17
Study 23271206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OLH and TLH
Number of subjects: 17
Study 21586501 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children (SET‐C)
Number of subjects: 0
Study 21586501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 21586501 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 0
Study 17950038 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg)
Number of subjects: 0
Study 17950038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16933524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based telephone protocol
Number of subjects: 212
Study 16933524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study 12439628 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 104
Study 12439628 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 104
Study 12439628 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prolactin (BLP)
Number of subjects: 104
Study 12439628 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP/LNAA ratio
Number of subjects: 104
Study 12439628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TRP/LNAA values
Number of subjects: 104